{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:15:18Z","timestamp":1790115318929,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":685,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s13311-021-01128-0","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T21:21:32Z","timestamp":1632777692000},"page":"2639-2650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"18","author":[{"given":"Chun-Pai","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Mao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hsuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-7800","authenticated-orcid":false,"given":"Ping-Tao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-5358","authenticated-orcid":false,"given":"Shuu-Jiun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01128-0_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","article-title":"Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment","volume":"71","author":"Bigal","year":"2008","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01128-0_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/0333102412468677","article-title":"Chronic migraine and chronic daily headache in the Asia-Pacific region: a systematic review","volume":"33","author":"Stark","year":"2013","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-021-01128-0_bib3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1468-2982.2002.00384.x","article-title":"Chronic daily headache in a tertiary care population: correlation between the International Headache Society diagnostic criteria and proposed revisions of criteria for chronic daily headache","volume":"22","author":"Bigal","year":"2002","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-021-01128-0_bib4","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38: 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"10.1007\/s13311-021-01128-0_bib5","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","article-title":"Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study","volume":"52","author":"Buse","year":"2012","journal-title":"Headache"},{"key":"10.1007\/s13311-021-01128-0_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"key":"10.1007\/s13311-021-01128-0_bib7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1590\/0004-282X20130066","article-title":"Latin American consensus on guidelines for chronic migraine treatment","volume":"71","author":"Giacomozzi","year":"2013","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1007\/s13311-021-01128-0_bib8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/0333102414547138","article-title":"Adherence to oral migraine-preventive medications among patients with chronic migraine","volume":"35","author":"Hepp","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-021-01128-0_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","article-title":"The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice","volume":"59","author":"American","year":"2019","journal-title":"Headache"},{"key":"10.1007\/s13311-021-01128-0_bib10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"Silberstein","year":"2007","journal-title":"Headache"},{"key":"10.1007\/s13311-021-01128-0_bib11","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Diener","year":"2007","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-021-01128-0_bib12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults","volume":"38","author":"Tassorelli","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-021-01128-0_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","article-title":"Current and emerging evidence-based treatment options in chronic migraine: a narrative review","volume":"20","author":"Agostoni","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1007\/s13311-021-01128-0_bib14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1007\/s13311-021-01128-0_bib15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1037\/pha0000148","article-title":"The efficacy and tolerability of paliperidone in mania of bipolar disorder: A preliminary meta-analysis","volume":"25","author":"Chang","year":"2017","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1007\/s13311-021-01128-0_bib16","doi-asserted-by":"crossref","unstructured":"Chen JJ, Zeng BS, Wu CN, et al. Association of Central Noninvasive Brain Stimulation Interventions With Efficacy and Safety in Tinnitus Management: A Meta-analysis. JAMA Otolaryngol Head Neck Surg 2020.","DOI":"10.1001\/jamaoto.2020.1497"},{"key":"10.1007\/s13311-021-01128-0_bib17","doi-asserted-by":"crossref","unstructured":"Hsieh MT, Tseng PT, Wu YC, et al. Effects of different pharmacologic smoking cessation treatments on body weight changes and success rates in patients with nicotine dependence: A network meta-analysis. Obes Rev 2019.","DOI":"10.1111\/obr.12835"},{"key":"10.1007\/s13311-021-01128-0_bib18","doi-asserted-by":"crossref","unstructured":"Su KP, Tseng PT, Lin PY, et al. Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms: A Systematic Review and Meta-analysis. JAMA Netw Open 2018;1: e182327.","DOI":"10.1001\/jamanetworkopen.2018.2327"},{"key":"10.1007\/s13311-021-01128-0_bib19","doi-asserted-by":"crossref","first-page":"15908","DOI":"10.1038\/s41598-019-52205-6","article-title":"Therapeutic effects of methylphenidate for attention-deficit\/hyperactivity disorder in children with borderline intellectual functioning or intellectual disability: A systematic review and meta-analysis","volume":"9","author":"Sun","year":"2019","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-021-01128-0_bib20","doi-asserted-by":"crossref","unstructured":"Tseng PT, Chen YW, Chung W, et al. Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study. Medicine (Baltimore) 2016;95: e2475.","DOI":"10.1097\/MD.0000000000002475"},{"key":"10.1007\/s13311-021-01128-0_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12888-016-0718-8","article-title":"Significant treatment effect of adjunct music therapy to standard treatment on the positive, negative, and mood symptoms of schizophrenic patients: a meta-analysis","volume":"16","author":"Tseng","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1007\/s13311-021-01128-0_bib22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.euroneuro.2016.03.001","article-title":"Light therapy in the treatment of patients with bipolar depression: A meta-analytic study","volume":"26","author":"Tseng","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1007\/s13311-021-01128-0_bib23","doi-asserted-by":"crossref","unstructured":"Tseng PT, Yang CP, Su KP, et al. The association between melatonin and episodic migraine: a pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. J Pineal Res 2020; e12663.","DOI":"10.1111\/jpi.12663"},{"key":"10.1007\/s13311-021-01128-0_bib24","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1038\/s41598-020-64910-8","article-title":"Antidepressants during and after Menopausal Transition: A Systematic Review and Meta-Analysis","volume":"10","author":"Wu","year":"2020","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-021-01128-0_bib25","doi-asserted-by":"crossref","unstructured":"Wu YC, Tseng PT, Tu YK, et al. Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis. JAMA Psychiatry 2019.","DOI":"10.1001\/jamapsychiatry.2018.4365"},{"key":"10.1007\/s13311-021-01128-0_bib26","doi-asserted-by":"crossref","unstructured":"Yang CP, Tseng PT, Pei-Chen Chang J, Su H, Satyanarayanan SK, Su KP. Melatonergic agents in the prevention of delirium: A network meta-analysis of randomized controlled trials. Sleep Med Rev 2020;50: 101235.","DOI":"10.1016\/j.smrv.2019.101235"},{"key":"10.1007\/s13311-021-01128-0_bib27","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1177\/0022034519870466","article-title":"Prevention of Postdental Procedure Bacteremia: A Network Meta-analysis","volume":"98","author":"Zeng","year":"2019","journal-title":"J Dent Res"},{"key":"10.1007\/s13311-021-01128-0_bib28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2215-0366(20)30137-1","article-title":"Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis","volume":"7","author":"Zhou","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1007\/s13311-021-01128-0_bib29","first-page":"951","volume":"15","author":"White","year":"2015","journal-title":"Network meta-analysis. The Stata Journal"},{"key":"10.1007\/s13311-021-01128-0_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1007\/s13311-021-01128-0_bib31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1526-4610.2007.00963.x","article-title":"Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse","volume":"48","author":"Freitag","year":"2008","journal-title":"Headache"},{"key":"10.1007\/s13311-021-01128-0_bib32","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/j.1526-4610.2009.01566.x","article-title":"A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study","volume":"49","author":"Mathew","year":"2009","journal-title":"Headache"},{"key":"10.1007\/s13311-021-01128-0_bib33","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-021-01128-0_bib34","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-021-01128-0_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1526-4610.2010.01796.x","article-title":"A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine","volume":"51","author":"Cady","year":"2011","journal-title":"Headache"},{"key":"10.1007\/s13311-021-01128-0_bib36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/head.12250","article-title":"An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine","volume":"54","author":"Cady","year":"2014","journal-title":"Headache"},{"key":"10.1007\/s13311-021-01128-0_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/WNL.0000000000002801","article-title":"TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points","volume":"87","author":"Bigal","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01128-0_bib38","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the Preventive Treatment of Chronic Migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01128-0_bib39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01128-0_bib40","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01128-0_bib41","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/0333102419858355","article-title":"Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1007\/s13311-021-01128-0_bib42","doi-asserted-by":"crossref","unstructured":"Kontopantelis E, Springate DA, Reeves D. A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses. PLoS One 2013;8: e69930.","DOI":"10.1371\/journal.pone.0069930"},{"key":"10.1007\/s13311-021-01128-0_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14737175.2018.1419867","article-title":"Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life","volume":"18","author":"Tassorelli","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-021-01128-0_bib44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline","volume":"331","author":"Silberstein","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-021-01128-0_bib45","doi-asserted-by":"crossref","unstructured":"Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology 2019;92: e2309-e2320.","DOI":"10.1212\/WNL.0000000000007497"},{"key":"10.1007\/s13311-021-01128-0_bib46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"}],"updated-by":[{"DOI":"10.1007\/s13311-021-01135-1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000}}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01128-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01128-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01128-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T05:55:47Z","timestamp":1704174947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923007298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1878747923007298"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01128-0","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s13311-021-01135-1","asserted-by":"object"}]},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01128-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01135-1","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}